Pharmaceutical Technology
BMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year.
Pharmaceutical Technology
BMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year.
Pharmaceutical Technology
BMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year.